Cephalon Inc – ‘8-K’ for 5/8/97

As of:  Friday, 5/9/97   ·   For:  5/8/97   ·   Accession #:  893220-97-914   ·   File #:  0-19119

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Form 8-K for Cephalon, Inc.                            4     10K 
 2: EX-99.1     Press Release Dated May 8, 1997                        2±     7K 

8-K   —   Form 8-K for Cephalon, Inc.
Document Table of Contents

8-K
1st Page of 4
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
 PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 May 8, 1997
 (Date of earliest event reported)

Cephalon, Inc.
(Exact name of registrant as specified in its charter)

                                                                [Download Table]
                                                                     
       Delaware                             0-19119       23-2484489 
(State or other jurisdiction              (Commission   (IRS Employer
of incorporation or organization)         File Number)      ID No.)  

         145 Brandywine Parkway                                      
       West Chester, Pennsylvania                          19380     
(Address of principal executive offices)                 (Zip Code)  

(610) 344-0200
(Registrant's telephone number, including area code)

Not Applicable
(Former name, former address and former fiscal year,
 if changed since last report)

8-K
2nd Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 2nd
ITEM 5.  OTHER EVENTS.                                                          

On May 8, 1997, Cephalon, Inc. (the "Registrant") announced that the  
Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food 
and Drug Administration had found, by a vote of 6 to 3, that there was not      
substantial evidence that MYOTROPHIN(R) (rhIGF-1 or mecasermin) Injection is    
effective in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's
disease).                                                                       

     The Registrant hereby incorporates by reference the Press Release, which is
attached hereto as Exhibit 99.1 and made a part hereof, into this Item 5.       

ITEM 7.  FINANCIAL STATEMENTS AND EXHIBITS.                                     

(a)      Financial Statements of Business Acquired: None      

(b)      Pro Forma Financial Information: None                

   (c)      Exhibits: Reference is made to the Exhibit Index annexed
hereto and made a part hereof.              

8-K
3rd Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 3rd
SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the    
undersigned thereunto duly authorized.                                          

                      CEPHALON, INC.

Date: May 8, 1997                           By: /s/ Bruce A. Peacock            
                                   ---------------------
                                    Bruce A. Peacock
                                                Executive Vice President and
                                           Chief Operating Officer

8-K
Last Page of 4
TOC
1st
Previous
Next
↓Bottom
Just 4th
 EXHIBIT INDEX

EXHIBIT                                                              PAGE       
-------                                                              ----       

99.1              Press Release dated May 8, 1997                               

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘8-K’ Filing		Date		First		Last			Other Filings
Filed on:		5/9/97							424B3
For Period End:		5/8/97		1		4
									List all Filings